Department of Biostatistics, Novo Nordisk, Aalborg, Denmark.
Department of Health Science and Technology, Aalborg University, Aalborg, Denmark.
Pharmacol Res Perspect. 2024 Apr;12(2):e1185. doi: 10.1002/prp2.1185.
The adherence to oral antidiabetic drugs (OADs) among people with type 2 diabetes (T2D) is suboptimal. However, new OADs have been marketed within the last 10 years. As these new drugs differ in mechanism of action, treatment complexity, and side effects, they may influence adherence. Thus, the aim of this study was to assess the adherence to newer second-line OADs, defined as drugs marketed in 2012-2022, among people with T2D. A systematic review was performed in CINAHL, Cochrane Trials, Embase, PubMed, PsycINFO, and Scopus. Articles were included if they were original research of adherence to newer second-line OADs and reported objective adherence quantification. The quality of the articles was assessed using JBI's critical appraisal tools. The overall findings were reported according to the preferred reporting items for systematic reviews and meta-analyses (PRISMA) guidelines and summarized in a narrative synthesis. All seven included articles were European retrospective cohort studies investigating alogliptin, canagliflozin, dapagliflozin, empagliflozin, and unspecified types of SGLT2i. Treatment discontinuation and medication possession ratio (MPR) were the most frequently reported adherence quantification measures. Within the first 12 months of treatment, 29%-44% of subjects on SGLT2i discontinued the treatment. In terms of MPR, 61.7%-94.9% of subjects on either alogliptin, canagliflozin, dapagliflozin, empagliflozin or an unspecified SGLT2i were adherent. The two investigated adherence quantification measures, treatment discontinuation and MPR, suggest that adherence to the newer second-line OADs may be better than that of older OADs. However, a study directly comparing older and newer OADs should be done to verify this.
2 型糖尿病患者（T2D）对口服降糖药（OAD）的依从性并不理想。然而，在过去 10 年中，新的 OAD 已上市。由于这些新药在作用机制、治疗复杂性和副作用方面存在差异，它们可能会影响依从性。因此，本研究旨在评估 T2D 患者对新型二线 OAD 的依从性，新型二线 OAD 定义为 2012-2022 年上市的药物。我们在 CINAHL、Cochrane 试验、Embase、PubMed、PsycINFO 和 Scopus 中进行了系统评价。纳入的文章必须是关于新型二线 OAD 依从性的原始研究，并报告客观的依从性量化指标。使用 JBI 的批判性评估工具评估文章的质量。总体结果根据系统评价和荟萃分析的首选报告项目（PRISMA）指南进行报告，并以叙述性综合报告。所有纳入的七篇文章均为欧洲回顾性队列研究，调查了阿格列汀、卡格列净、达格列净、恩格列净和未特指类型的 SGLT2i。停药和药物使用比例（MPR）是最常报告的依从性量化指标。在治疗的前 12 个月内，29%-44%的 SGLT2i 使用者停止了治疗。在 MPR 方面，61.7%-94.9%的阿格列汀、卡格列净、达格列净、恩格列净或未特指类型的 SGLT2i使用者依从性良好。这两项调查的依从性量化指标，即停药和 MPR，表明新型二线 OAD 的依从性可能优于旧的 OAD。然而，应该进行一项直接比较新旧 OAD 的研究来验证这一点。
